| Literature DB >> 21718055 |
Rajendra P Tanpure1, Benson L Nguyen, Tracy E Strecker, Savannah Aguirre, Suman Sharma, David J Chaplin, Bronwyn G Siim, Ernest Hamel, John W Lippert, George R Pettit, Mary Lynn Trawick, Kevin G Pinney.
Abstract
The natural products combretastatin A-4 (CA4) and combretastatin A-1 (CA1) are potent cancer vascular disrupting agents and inhibitors of tubulin assembly (IC₅₀ = 1-2 μM). The phosphorylated prodrugs CA4P and CA1P are undergoing human clinical trials against cancer. CA1 is unique due to its incorporation of a vicinal phenol, which has afforded the opportunity to prepare both diphosphate and regioisomeric monophosphate derivatives. Here, we describe the first synthetic routes suitable for the regiospecific preparation of the CA1-monophosphates CA1MPA (8a/b) and CA1MPB (4a/b). The essential regiochemistry necessary to distinguish between the two vicinal phenolic groups was accomplished with a tosyl protecting group strategy. Each of the four monophosphate analogues (including Z and E isomers) demonstrated in vitro cytotoxicity against selected human cancer cell lines comparable to their corresponding diphosphate congeners. Furthermore, Z-CA1MPA (8a) and Z-CA1MPB (4a) were inactive as inhibitors of tubulin assembly (IC₅₀ > 40 μM), as anticipated in this pure protein assay.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21718055 PMCID: PMC3275140 DOI: 10.1021/np200104t
Source DB: PubMed Journal: J Nat Prod ISSN: 0163-3864 Impact factor: 4.050